Does the High-Dose Flu Shot Lower Alzheimer's Risk?
Getting the high-dose flu shot instead of the standard one was linked to fewer Alzheimer dementia diagnoses over about two years in a new study of older adults. That's a promising signal, but it comes from insurance records, it wasn't statistically significant under some of the researchers' own checks, and it hasn't been independently confirmed. The solid reason to choose high-dose this fall hasn't changed. It protects people 65 and older from flu better than the standard shot, and two other vaccines for your age group are equally preferred choices.
Comparing two flu shots instead of shot versus no shot
Researchers had linked flu vaccination to less dementia before. Most of those studies compared vaccinated people with unvaccinated people, and the results were mixed: several cohorts and meta-analyses found lower risk, while others found no protective association. The weakness is built in. People who get flu shots can differ from unvaccinated people in healthcare use and health habits, and they differ in other ways no database fully captures.
The new study, published in Neurology this year by the UTHealth Houston group, avoids part of that problem because everyone in it was vaccinated. It's still observational, though, so it can't show the shot caused the difference. High-dose vaccines carry four times the antigen of standard ones. The high-dose group's recorded risk of Alzheimer dementia stayed lower from the first month through month 25.
The group's 2022 study compared a flu shot with no flu shot, and the new one compares a higher dose with a standard dose, so the two estimates can't be stacked or ranked.
Where the signal gets shaky
The weaknesses start with how dementia was counted. Diagnoses came from billing codes and prescriptions for Alzheimer drugs. The analysis didn't include memory-test results. Follow-up was short for a disease that develops over many years, so a gap that opens within months may say more about when diagnoses got recorded than about disease prevented. The authors ran several checks for bias, and the results pointed in both directions. A negative-control analysis, which looks for an apparent effect on an outcome a flu shot shouldn't change, found no significant difference, which is reassuring. But when the team counted only more specific dementia codes, leaving out vague ones like unspecified dementia, the difference was no longer statistically significant. It also lost significance among people who reliably took cholesterol-lowering drugs, a group researchers use to test whether health-conscious habits are behind a result. None of this proves bias explains the whole association, and fewer cases in these checks also made the estimates less precise. Losing significance later in follow-up also doesn't show that a benefit ends then.
Two other points came up in the coverage. The effect was described as stronger in women, but different significance windows for women and men don't establish that the vaccine works differently by sex. And nobody knows how a high-dose shot would protect the brain if it does. Preventing flu itself is one proposed explanation, and broader immune effects are another. The study did not test whether breakthrough flu infections account for the gap.
The proven reason to ask for high-dose
The flu benefit has randomized trials behind it. Across trial syntheses in adults 65 and older, high-dose shots reduced lab-confirmed flu and flu hospitalizations by roughly a quarter to a third or more compared with standard dose. The cost is more sore arms, swelling, headache, and tiredness. These are mostly mild and pass within days, and serious adverse events weren't significantly more common. CDC has preferred high-dose, recombinant, or adjuvanted vaccines for this age group since the 2022-23 season, years before the dementia study appeared. A severe allergic reaction to a component other than egg rules out shots containing that component. If you developed Guillain-Barré syndrome within six weeks of a previous flu shot, that history is worth going over with a clinician before you get another.
Choosing among the preferred vaccines
The dementia study pitted high-dose only against standard dose, so it can't tell you whether high-dose does anything for memory that recombinant or adjuvanted vaccines don't. On flu protection, a large randomized comparison during the 2023-24 season found no significant difference between adjuvanted and high-dose vaccines in adults 65 and older.
| Vaccine option | CDC guidance for age 65+ | What the dementia study shows |
|---|---|---|
| High-dose inactivated | Preferred | Linked to fewer recorded Alzheimer diagnoses than standard dose; cause unproven |
| Recombinant | Preferred | Not compared with high-dose |
| Adjuvanted inactivated | Preferred | Not compared with high-dose |
| Standard-dose unadjuvanted | Fallback when no preferred option is available | Comparison group |
If your pharmacy has high-dose, asking for it gets you better flu protection than standard dose, plus a possible memory benefit that researchers now have a concrete reason to test. If it has recombinant or adjuvanted instead, either is an equally preferred choice. If none of the three is in stock, CDC advises getting another age-appropriate shot at that visit, because a dementia advantage that may not exist isn't worth giving up flu protection you could have now. To count on the memory benefit, you'd need a randomized trial that tests cognition at the start, confirms dementia clinically, runs for years, and ideally compares all three preferred vaccines.